New treatments for pemphigus, a serious autoimmune skin disease
Official title: Novel treatments for Autoimmune Disease
Funded at Astero Erado INC · NIH-10852934 · Data updated 2026-11-12
This study is looking for a new and safer way to treat pemphigus, a condition that causes painful blisters, by targeting the specific antibodies that cause the problem, so patients can feel better faster and with fewer side effects.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Astero Erado INC NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $293,489 |
| NIH project number | 5R43AI179252-02 |
| Project ID | NIH-10852934 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pemphigus, particularly those experiencing severe symptoms or adverse effects from current treatments.
✕Less likely to help
Patients with other autoimmune diseases or those not diagnosed with pemphigus may not benefit from this research.
What this research studies
This research aims to develop a novel therapeutic approach for treating pemphigus, a condition characterized by painful blisters on the skin and mucosal surfaces. The project focuses on targeting the autoantibodies that disrupt skin cell adhesion, which are responsible for the disease's symptoms. Current treatments can have significant side effects and long onset times, so this research seeks to provide a more effective and safer alternative. Patients may benefit from a treatment that acts directly on the underlying cause of the disease rather than just managing symptoms.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and safer treatment for pemphigus, reducing pain and improving quality of life for patients.
How similar studies have gone: While there have been various approaches to treating pemphigus, this specific therapeutic strategy is novel and has not been extensively tested in prior research.
Where this research is happening
-
Astero Erado INC
College Station, United States Active
Researchers
- Principal investigator: Kannanganat Sidharthan, Sunil — Astero Erado INC
- Study coordinator: Kannanganat Sidharthan, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.